XML 55 R45.htm IDEA: XBRL DOCUMENT v3.19.1
Collaborations and Other Arrangements (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Revenue $ 5,092.2 $ 4,963.8      
R&D expense 1,230.5 1,107.5      
Trajenta          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Revenue 131.9 141.1      
Jardiance          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Revenue 203.6 151.0      
Basaglar          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Revenue 251.4 166.0      
Milestone Payments, Development and Regulatory, Capitalized, Cumulative | Trajenta          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Milestones (deferred) capitalized 446.4        
Milestone Payments, Development and Regulatory, Capitalized, Cumulative | Jardiance          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Milestones (deferred) capitalized 289.0        
Milestone Payments, Development and Regulatory, Capitalized, Cumulative | Basaglar          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Milestones (deferred) capitalized $ (250.0)        
Royalty Agreement Terms | Olumiant          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Collaborative arrangement, rights and obligations, percentage 20.00%        
Research and Development Exp | Olumiant          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Collaborative arrangement, rights and obligations, percentage 30.00%        
Milestone Payments, Development and Regulatory, Expensed | Olumiant          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
R&D expense     $ 20.0 $ 30.0 $ 55.0
Milestone Payments, Development and Regulatory | Olumiant          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Milestones (deferred) capitalized $ 130.0        
Milestone Payments, Development and Regulatory | Tanezumab          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Milestones (deferred) capitalized 350.0        
Milestone Payments, Sales-based | Olumiant          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Milestones (deferred) capitalized 150.0        
Milestone Payments, Sales-based | Tanezumab          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Milestones (deferred) capitalized 1,230.0        
U.S.          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Revenue 2,890.8 2,795.6      
U.S. | Trajenta          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Revenue 47.4 54.1      
U.S. | Jardiance          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Revenue 125.2 95.0      
U.S. | Basaglar          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Revenue 198.2 126.7      
U.S. | Milestone Payments, Development and Regulatory, Capitalized (Deferred) | Olumiant          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Milestones (deferred) capitalized     $ 100.0    
Europe          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Revenue 900.3 864.2      
Europe | Milestone Payments, Development and Regulatory, Capitalized (Deferred) | Olumiant          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Milestones (deferred) capitalized       65.0  
Japan          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Revenue $ 543.7 $ 537.0      
Japan | Milestone Payments, Development and Regulatory, Capitalized (Deferred) | Olumiant          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Milestones (deferred) capitalized       $ 15.0